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ABSTRACT 
 
 
  
 The purpose of this project is to help inform the public about the technological advances 
and applications of stem cell therapies, and to describe some of the key legal and ethical issues 
that surround them. In the first and second chapters, the existing types of stem cells are explored 
and examples of their treatment of key diseases are discussed.  In the final two chapters, the 
legality and ethics of stem cell applications are discussed, and then each author provides their 
own individual conclusions at the end of the report. 
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PROJECT OBJECTIVES 
 
 The project objective of this IQP was to demonstrate the properties and applications of 
stem cell technologies, and investigate the controversies surrounding their uses in modern 
society.  In chapter one, stem cells are described and classified based on their sources and 
potential to differentiate.  Chapter two examines the applications of these various types of stem 
cells and their uses in medicine. The purpose of chapter three is to examine the ethical and moral 
concerns surrounding the use of stem cells and how they are obtained, in view of each of the five 
major world religions. Chapter four discusses federal and state U.S. laws, as well as international 
laws, governing the research and sourcing of usable stem cells. Finally, the authors provide a 
conclusion that best reflects their opinion on the use of stem cells and the laws that govern them. 
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Chapter-1:  Stem Cell Types 
Lee Keaffer 
 
 
Introduction 
 
Stem cells are long-lived undifferentiated cells with the ability to differentiate into 
specialized cells. These cells are used by the body to replenish aged cells within tissues.  Due to 
this property, they are the foundation for the field of regenerative medicine, and could be used to 
replenish diseased cells in a patient.  However, obtaining some types of stem cells destroys 
embryos, which some individuals argue is “murder”, making stem cells is one of the most 
controversial topics in biology today based on ethical and moral concerns.  However, there are 
many misconceptions about stem cells. For example, many people believe there is only one type 
of stem cell, and that using all stem cells destroys unborn embryos. Many people also believe 
that all stem cells have the ability to differentiate into any cell in the body. While these are 
characteristic of some stem cells, they are not characteristic of all. In this chapter, I will dispel 
some of the myths about stem cells, as I describe the characteristics of different types of stem 
cells, how we identify them, where we find them from, and how we isolate them. 
 
Embryonic Stem Cells 
Embryonic stem (ES) cells were first derived in 1981 in mice (Martin, 1981; Evans and 
Kaufman, 1981). It was not until 1998, however, that human embryonic stem cells were derived 
(Thomson et al., 1998). The reason for the time lapse between the discovery of the mouse and 
human ES cells was due in large part to the taboo nature of the use of a human embryo for 
research. ES cells are pluripotent cells derived from the inner cell mass of the blastocyst stage of 
a fertilized embryo. This stage occurs roughly five days after fertilization. During normal 
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development, the blastocyst stage occurs just before embryo implantation into the uterus wall. At 
this point, the cells of the embryo have already gone through one stage of differentiation. The 
inner cell mass cells have differentiated to be able to form any cell of the fully-grown adult, 
while the outer layer of cells has differentiated to become the extra-embryonic structures, such as 
the placenta.   To prepare ES cells for experiments, scientists perform in vitro fertilization (IVF) 
(Figure-1).  As the fertilized egg divides to the 8-cvell stage, the cells are totipotent, meaning 
they can form an entire embryo.  At around day-5 the blastocyst forms (diagram center, with the 
inner cell mass shown in blue).  The isolated ES cells are plated onto a feeder layer of cells in a 
dish that provides a scaffold and growth factors that aid ES cell survival (diagram, lower).  When 
the technique was first developed in 1998, the feeder cells were mouse fibroblasts, but eventually 
due to worries about mixing human ES cells with animal fibroblast cells when the ES cells were 
to be used for therapy, the feeder layer was switched to human cells, or was completely 
eliminated by adding the growth factors exogenously (Klimanskaya et al., 2005).   
 
 
 
 
Figure-1: Isolation and Culture of Human Embryonic Stem 
Cells.  Shown is a summary of how ES cells are derived from 
IVF embryos and grown on a layer of feeder cells.  (Thomson, 
1998) 
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With respect to IVF embryos as the source of ES cells for research, currently in the US 
such embryos must be obtained from IVF clinics where the embryos are originally created for 
reproductive purposes.  IVF embryos cannot be created in the US solely for research purposes.  
While most of the IVF embryos are used to treat infertility, around 2.8% of them are not needed 
by the donors, so with donor consent these unused blastocysts can be used for research to make 
ES cell lines.  
When ES cells replicate, either they can create more ES cells, which makes them long-
lived, or under the right conditions they can differentiate into other cells.  Scientists have spent 
considerable time analyzing which proteins are required to keep ES cells pluripotent versus 
which proteins are needed for differentiation into a particular type of cell.  Although scientists 
first used feeder layer cells when growing ES cells, researchers at Yale have found what they 
believe to be the minimal culture requirements for proliferation of human ES cells (Emanuel, 
2006). They found that, when cultured with growth factor Wnt3, basic fibroblast growth factor, 
insulin, transferrin, B-cell activating factor April/BAFF, cholesterol, and albumin, the human ES 
cells could proliferate and stay pluripotent.  They called this mixture of proteins and lipids 
“human embryonic stem cell cocktail” (HESCO (Emanuel, 2006).  Although this cocktail allows 
the ES cells to replicate, scientists still do not completely understand what keeps ES cells 
pluripotent, nor do we understand how to differentiate them in vitro into all other types of cells.  
There are, however, some proteins and genes which serve as markers for ES cells, and which 
could be the key to their pluripotency. For example, the presence of Oct-4 transcription factor, 
and its continued expression, is one of the key markers used to identify ES cells. The expression 
of this protein is also necessary for the cell to retain its pluripotency. Also, the protein Nanog has 
been found to be a marker of ES cells in mice, and also is necessary for the ES cell to remain 
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undifferentiated.  Nanog is present in human ES cells, but not to the same extent as in mice. 
There are also genes present in ES cells that are more expressed than in their differentiated 
counterparts. Studies have found that up to 918 genes whose expression is higher in ES cells. 
There is also another new and exciting way to create human ES cells using a patient’s 
own DNA.  If this technique of ES cell cloning using somatic cell nuclear transfer (SCNT) can 
be developed, it would allow ES cells to be created that are genetically identical to a patient, 
increasing their engraftment potential in the same patient.  The SCNT method normally involves 
removing the nucleus from an egg and replacing it with a diploid nucleus from a skin fibroblast 
cell.  The method was developed in 1996 in sheep (Campbell et al., 1996), and was reported in 
2005 for humans (Hwang et al., 2005), but the latter study turned out to be fraudulent.  A recent 
modification of the SCNT technique was developed in which a patient’s fibroblast diploid 
nucleus is injected into a haploid egg to create a triploid embryo from which triploid ES cells can 
be derived (Noggle et al., 2011).  By leaving the egg’s haploid nucleus intact and injecting the 
diploid fibroblast DNA directly into the nucleus, Scott Noggle was able to create a triploid (three 
complete chromosome sets, two from the human donor and one from the egg donor) from which 
triploid pluripotent cells could be derived.  This process, while controversial, could make it 
possible to create patient-specific tissue to treat diseases, without the risk of rejection by the 
recipient of the tissue (Coombs, 2011). 
While ES cells are medically some of our most exciting cells, as they are pluripotent, 
they are also the most controversial since an embryo is usually destroyed to obtain them. The 
debate (discussed in Chapter-3) centers on when life begins, and the status of excess IVF 
embryos.  And laws have been enacted in some countries, including the US under the Bush 
administration (discussed in Chapter-4), preventing federal funding of embryo research. 
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Induced Pluripotent Stem Cells  
Induced pluripotent stem (iPS) cells are adult differentiated cells, usually skin fibroblast 
cells, which have been de-differentiated to a state of pluripotency. They are some of the newest 
stem cells discovered, and are the subject of some of the most exciting research. A patient’s 
fibroblast cells are de-differentiated by transfecting them with specific genes (discussed below) 
which induce the pluripotent state. The iPS cells are almost identical to ES cells, in that they 
express many of the same genes, have many of the same transcription factors (including Nanog 
and Oct4 which were discussed earlier), and appear to be capable of broad differentiation.  
The technique was first developed in mice (Takahashi and Yamanaka, 2006) and was later 
applied to humans (Takahashi et al., 2007).  When the technique was first developed, four genes 
were used to induce the pluripotency: Oct3/4, SOX2, KLF4, and c-MYC (Figure-2). The genes 
were inserted in the fibroblast cells using retroviruses, which was a controversial technique as 
the vector could cause cancer in some cases.   
 
 
 
 
 
 
 
 
 
 
 
Figure-2: Diagram of the Roles of Oct3/4, Sox2, KLF4, and c-MYC in Creating iPS 
Cells.  Some of the proteins open up the chromatin allowing reprogramming, while 
others help induce the de-differentiation.  (Yamanaka, 2007) 
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As can be seen in Figure-2, c-Myc induces the opening of chromatin, allowing its 
reprogramming, and increases the immortality of the cells.  However, c-Myc also can induce 
oncogenesis.  c-Myc is an oncogene present in human tumors. KLF4 has been identified as both 
an oncogene and a tumor suppressor, and plays a crucial role in the switch from cell proliferation 
to cell differentiation. This protein also can cause the cells to become cancerous. This is 
countered by Oct3/4, which, along with Sox2, cause the cell to develop into a pluripotent, ES-
like stem cell. Like KLF4, Oct3/4 also plays a key role in determining when cells will 
differentiate. Even with these four genes introduced to the epithelial cells, only about 1% of the 
cells achieve induced pluripotency (Yamanaka, 2007).  
Current research on iPS cells focuses on how potent they are, and identifying the least 
number of required inducing factors.  Some scientists claim iPS cells are extremely similar to ES 
cells, claiming they have the same growth rate, telomerase is active (as it is in ES cells), and 
pluripotency genes like Nanog are active in the iPS cells. In mice, iPS cell have been shown to 
create entire body structures, showing their high potency (Boland et al., 2009).  Much research 
has focused on eliminating the oncogenes KLF4 and c-MYC in the treatment.  Recent 
discoveries have shown that NANOG and LIN28 can be used in place of KLF4 and c-MYC.  
These cells contain very similar markers to ES cells, and to the other iPS cells, and their 
differentiation to full body structures of mice was possible (Baker, 2007; Kim et al., 2008). 
However, other scientists argue that iPS cells grow slower than ES cells and contain mutations in 
their DNA (Gore et al., 2011), so it is still debatable whether iPS cells can serve as a replacement 
for ES cells.   
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Parthenogenetic Stem Cells 
Parthenogenesis is the Greek word for “virgin birth”.  In the world of biology, 
parthenogenesis is the mode of asexual reproduction in which a female egg begins cellular 
division and creates an embryo, with no involvement from sperm. This process is used in nature 
in some insect species to rapidly create worker bees and ants.  Although parthenogenesis does 
not normally exist in mammals, scientists have developed artificial methods using chemicals to 
stimulate egg replication through the blastocyst stage from which ES cells can be obtained 
(Weiss, 2001).  Fertilization generally replaces one of the sets of chromosomes. However, with a 
chemical or electrical stimulus, some eggs can be induced to proceed as if fertilized, while 
retaining their second chromosome set (Figure-3).  However, this embryo generally dies within 
a few days, so these embryos are not as viable as fertilized embryos. Perhaps parthenote stem 
cells could serve as a replacement for ES cells and would be less of a concern ethically, as full 
embryos are not used.  
 
 
 
 
 
 
 
Figure-3:  Diagram of Artificial Parthenogenesis.  In this 
process, an egg is induced to begin cell division without extruding 
its second set of chromosomes, keeping it diploid.  The egg can 
divide to the blastula stage from which ES cells can be derived.  
(Vrana et al., 2003) 
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Scientists first achieved success with monkey parthenote ES cell lines in 2001 (Mitalipov 
et al., 2001).  Mouse parthenote ES cells were derived in 2007 (Kim et al., 2007).  More recently, 
David Wininger was able to grow a human parthenote to the blastocyst stage and extract ES cells 
(Vrana et al., 2006). This is very exciting, because these parthenote ES (pES) cells may be as 
potent as normal ES cells, although more research will be required to prove this.  This is also 
very exciting from an ethical point of view.  Because parthenote eggs are not fertilized, and the 
created blastocyst cannot develop into a viable embryo, parthenote embryos may have fewer 
ethical concerns (discussed in Chapter-3) (Pagan, 2003). 
 
Adult Stem Cells 
In contrast to embryonic stem cells, adult stem cells (ASCs) are isolated from adult 
tissues (or umbilical cord) and do not destroy an embryo to obtain them.  There are many 
different types of adult stem cells, which can range from adult hematopoietic stem cells, which 
are the most researched form of stem cells, to neuronal stem cells, cardiac stem cells, epithelial 
stem cells, and mesenchymal stem cells. In this chapter section, I will focus on four types of 
adult stem cells: adult hematopoietic stem cells, neuronal stem cells, cardiac stem cells, and 
mesenchymal stem cells. 
 
Hematopoietic Stem Cells 
Hematopoietic stem cells (HSCs) are frequently called bone marrow stem cells, since this 
is their most common source. Due to the many different types of blood cells in the body, and the 
fact that many of them have short lives (around 90 days) and need to be replenished rapidly, 
 13 
there is a strong need for stem cells that can produce whatever type of blood cell is necessary. 
HSCs fill this role. These cells are not pluripotent, but they can differentiate into several types of 
related blood cells, so they are considered multipotent. HSCs have the ability to differentiate into 
any kind of blood cell, ranging from several types of white blood cells to platelets to red blood 
cells (Figure-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-4: Diagram of the Various Blood Cells Hematopoietic Stem Cells Can 
Differentiate Into.  HSCs in this case are isolated from bone marrow (diagram, left), and 
can form lymphoid or myeloid progenitor cells from which all other blood cells are 
derived.  (NIH, 2006) 
 
Hematopoietic stem cells were first seen in 1956, when three separate laboratories found 
that when mice were exposed to lethal amounts of radiation, if they were injected with bone 
marrow, their damaged blood-forming systems regenerated (NIH, 2006). This finding proved 
valuable for treating patients affected by radiation poison in Japan, and was also very important 
for the treatment of cancer, because it gave the possibility of radiation therapy to destroy tumors 
 14 
followed by bone marrow transplants to replace the blood components.  The first human bone 
marrow transplants for cancer were performed in 1957 (Thomas et al., 1957). 
HSCs are traditionally isolated from bone marrow, but more recently are obtained from 
the peripheral blood of donors injected with hormones to mobilize their HSCs from the marrow 
into the blood.  HSCs can also be found in umbilical cord blood, and these HSCs may be better 
suited for therapies than bone marrow-derived HSCs, as they are more primitive so are less likely 
to be rejected by the host (Viacord, 2011).   
In addition to performing bone marrow transplants, HSCs can sometimes be purified 
prior to injection into a host.  The most popular method of HSC purification is labeling them 
with fluorescent antibodies against a cell surface marker specific for HSCs, such as CD-34.  The 
antibodies stick to the surface of HSCs, then the cells are passed through a cell sorter which 
separates labeled from unlabeled cells.  The cells can be sorted with a great deal of accuracy, 
however the process can be somewhat time consuming, and requires expensive equipment.   
Scientists continue to debate the best markers for identifying HSCs.  CD34 was the first one 
identified, but others include CD38, Lin, CD90, and CD133 (Domen et al., 2000). 
 
Neural Stem Cells 
In adults, neuronal stem cells (NSCs) are also present. Not long ago, it was thought that 
once neurons died in the adult body, they were gone for good.  However, in 1989, this was 
shown to be untrue with the finding of NSCs in the brain (Temple, 1989).  Further proof of the 
existence of NSCs was obtained in the mid 1990’s, in the fetal and adult brain, which have the 
ability to regenerate neurons under the right conditions. They found that these neuronal stem 
cells, “resemble cells in a developing fetus that give rise to the brain and spinal cord” (National 
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Institute of Health, 2009). They found that these cells had the ability to regenerate almost all of 
the cells present in the human brain.  
The presence of adult NSCs with the ability to regenerate the cells of the brain and 
central nervous system is a very exciting discovery, and increases our hope for treating 
neurodegenerative diseases. Methods to use NSCs to regenerate neural cells for a patient are 
already underway, by either growing the NSCs in culture and then treating with growth factors to 
differentiate the cells into the desired neural cell, or by treating a patient directly with specific 
growth factors to trigger stem cells inside the patient’s body to differentiate into the desired 
neural cell. 
 
Cardiac Stem Cells 
Just as the brain was thought to not be capable of regeneration, so was the heart, until 
cardiac stem cells (CSCs) were discovered.  First found in rats in 2003 (Beltrami et al., 2003), 
these multipotent cells could have the ability to repair damaged tissue in the heart. In rats with 
heart disease, CSCs were cultured and injected into the hearts where they helped repair it.  CSCs 
have also been found in humans (Laugwitz et al., 2005).  CSCs isolated from rats or humans with 
with heart disease were found to already be in the process of attempting to repair the heart. Now 
that scientists have located where the cardiac stem cells reside, the next step is to find how to 
increase their efficiency of repairing cardiac muscle, and this will be discussed in chapter-2. 
Figure-5 shows an image of human cardiac heart cells, with the blue cells representing stem 
cells, and the red cells cardiac muscle cells (Touchette, 2003). 
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Figure-5: Fluorescence Microphotograph of Human Cardiac Stem Cells.  Blue cells 
are stained with an antibody against cardiac stem cells, while red cells are stained with an 
antibody against cardiac muscle cells.  (Touchette, 2003) 
 
 
Mesenchymal Stem Cells 
Finally, in adults there are also mesenchymal stem cells (MSCs). These multipotent stem 
cells are present in bone marrow and in many other tissues of adults, and have the ability to 
differentiate into various connective tissues, such as muscle, fat, and cartilage (Barry and 
Murphy, 2004).  MSCs are usually isolated from bone marrow, and while they do not represent a 
large portion of the marrow cells, once isolated they can be cultured using normal culturing 
techniques.  In order to isolate them, cell fractioning is used based on cell density.  Like many 
other types of stem cells, MSCs can be identified using cell surface markers and antibodies that 
detect them.  For example, studies performed by Otto and Rao, and Deans and Mosley, found 
that markers CD 44, CD 29, and CD 90 are specific cell markers used to identify human MSC’s. 
It has also been found that human and rat MSC’s are lacking CD34, but can be identified using 
antigens Stro-1, SH2, SH3 and SH4, and that these cells are also positive for MHC-1 and Sca-1. 
These antibodies are not enough, however, to be used alone to test a culture of MSC’s for purity 
(Nardi, 2006). 
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MSCs have become widely used in the past few years, due to their multipotency, their 
relative ease of isolation and growth, and their isolation from adult not embryonic tissues.  They 
are thought to have widespread applications for replacing connective tissues in a variety of 
diseases. They are also exciting because, like many others of the adult stem cells, they can be 
removed from the patient themselves, which will negate the possibility of the recipients body 
rejecting the graft.  Some of the uses of MSCs will be discussed in greater detail in chapter-2. 
 
Chapter-1 Conclusion 
Stem cells are a very important and controversial topic, and are widely misunderstood by 
the general public. Understanding the various types of stem cells, where they come from, and 
what they do, is critical for changing the public opinion of stem cell research. I hope that this 
chapter has clarified the different types of stem cells, and has showed that not all stem cells come 
from embryos, and that not all stem cells are medically identical.  The moral and legal 
implications of the stem cells discussed in this chapter, as well as the possible uses of these stem 
cells, will be discussed in the following chapters. 
 
Chapter-1 Bibliography 
Baker, Monya (2007) Adult Cells Reprogrammed to Pluripotency, without Tumors.  Nature 
Reports Stem Cells. Nature Publishing Group: Science Journals, Jobs, and Information.  
06 Dec. 2007.  http://www.nature.com/stemcells/2007/0712/071206/full/stemcells.2007.124.html 
 
Barry F, Murphy M (2004) Mesenchymal Stem Cells: Clinical Applications and Biological 
Characterization.  International Journal of Biochemistry and Cell Biology, 36: 568-584. 
 
Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, et al. (2003) Adult Cardiac Stem Cells 
Are Multipotent and Support Myocardial Regeneration.  Cell, 114: 763-776.   
 
Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, et al. (2009) Adult Mice Generated From 
Induced Pluripotent Stem Cells.  Nature, 461: 91-94.   
 18 
 
Campbell KH, McWhir J, Ritchie WA, Wilmut I (1996) Sheep Cloned by Nuclear Transfer 
From a Cultured Cell Line.  Nature, 380: 64-66.   
 
Coombs, Amy (2011) New Way to Make Embryonic Stem Cells. The Scientist, October 5, 2011.   
http://the-scientist.com/2011/10/05/new-way-to-make-embryonic-stem-cells/ 
 
Domen J, Cheshier SH, Weissman IL (2000) The role of apoptosis in the regulation of 
hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation 
potential.  Journal of Experimental Medicine, 191: 253-264. 
 
Emanuel, Janet (2006) Minimal Nutritional Requirements For Growing Human Embryonic Stem 
Cells Established.  Medical  News Today. 
http://www.medicalnewstoday.com/medicalnews.php?newsid=40453&nfid=rssfeeds. 
 
Evans MJ, Kaufman MH (1981) Establishment in culture of pluripotential cells from mouse 
embryos.  Nature, 292(5819): 154-156.   
 
Gore A, Li Z, Fung H, Young J, Agarwal S, et al. (2011) Somatic Coding Mutations in Human 
Induced Pluripotent Stem Cells.  Nature, 471: 63-67.  
 
Hwang WS, Roh SI, Lee BC, Kang SK, Kwon DK, Kim S, et al. (2005) Patient-specific 
embryonic stem cells derived from human SCNT blastocysts.   Science,  308: 1777-1783.  
 
Kim K, Lerou P, Yabuuchi A, Lengerke C, Ng K, West J, Kirby A, Daly M, Daley G (2007) 
Histocompatible Embryonic Stem Cells by Parthenogenesis.  Science, 315: 482-486.   
 
Kim JB, Zaehres H, Wu G, Gentile L, Ko K, et al (2008) Pluripotent Stem Cells Induced from 
Adult Neural Stem Cells by Reprogramming with Two Factors.  Nature, 454: 646-650.   
 
Klimanskaya I, Chung Y, Meisner L, Johnson J, West MD, Lanza R (2005) Human Embryonic 
Stem Cells Derived Without Feeder Cells.  Lancet, 365(9471): 1636-1641. 
 
Laugwitz KL, Moretti A, Lam J, Gruber P, Chen Y, et al. (2005) Postnatal Isl1+ Cardioblasts 
Enter Fully Differentiated Cardiomyocyte Lineages.  Nature, 433: 647-653.   
 
Martin, Gail (1981) Isolation of a pluripotent cell line from early mouse embryos cultured in 
medium conditioned by teratocarcinoma stem cells.  Proc Natl Acad Sci USA, 78: 7634-7638.  
 
Mitalipov SM, Nusser KD, and Wolf DP (2001) Parthenogenetic Activation of Rhesus Monkey  
Oocytes and Reconstructed Embryos.  Biol Reprod,  65: (1) 253-259.  
http://www.biolreprod.org/content/65/1/253.full.pdf+html 
 
Nardi NB, Meirelles LS (2006) Mesenchymal Stem Cells: Isolation, In Vitro Expansion and 
Characterization. 
http://books.google.com/books?id=aGyqLIoP1kUC&pg=PA248&hl=en#v=onepage&q&f=false 
 19 
 
NIH Stem Cell Information (2006) Chapter-2: Bone Marrow (Hematopoietic) Stem Cells. 
http://stemcells.nih.gov/info/2006report/2006chapter2.htm 
 
Noggle S, Fung HL, Gore A, Martinez H, et al. (2011) Human Oocytes Reprogram Somatic 
Cells to a Pluripotent State.  Nature, 478: 70-75.   
 
Rebuilding the Nervous System with Stem Cells (2005) NIH, Stem Cells, Chapter-8.  
http://stemcells.nih.gov/info/scireport/chapter8.asp 
 
Rietze RL, Valcanis H, Brooker GF, Tim T, Anne VK, and Bartlett PF (2001) Purification of a 
Pluripotent Neural Stem Cell from the Adult Mouse Brain.  Nature, 412: 736-739.  
http://www.nature.com/nature/journal/v412/n6848/pdf/412736a0.pdf. 
 
Takahashi K, and Yamanaka S (2006) Induction of Pluripotent Stem Cells From Mouse 
Embryonic and Adult Fibroblast Cultures by Defined Factors.  Cell, 126: 663-676.   
 
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) 
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors.  Cell, 
131: 1-12.   
 
Temple S (1989) Division and Differentiation of Isolated CNS Blast Cells in Microculture. 
Nature, 340: 471–473.    
 
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM 
(1998) Embryonic Stem Cell Lines Derived From Human Blastocysts.  Science, 282: 1145-1147. 
 
Thomson JA, and Yu J (2006) Embryonic Stem Cells.  Department of Health and Human 
Services. http://stemcells.nih.gov/staticresources/info/scireport/PDFs/C.%20Chapter%201.pdf 
 
Touchette N (2003) Stem Cells Found in the Heart. 
http://www.genomenewsnetwork.org/articles/10_03/cardiac.shtml 
 
Viacord (2011) www.viacord.com 
 
Vrana KE, Hipp JD, Goss AM, McCool BA, Riddle D R, Walker SJ, et al. (2003) Nonhuman 
primate parthenogenetic stem cells.  Proceedings of the National Academy of Sciences USA, 
100(Supplement-1): 11911-11916.  http://www.pnas.org/cgi/content/full/100/suppl_1/11911 
 
Weiss, Rick (2001) Parthenotes Expand the Debate on Stem Cells. 
http://www.washingtonpost.com/ac2/wp-dyn/A18046-2001Dec9?language=printer 
 
Yamanaka, Shinya (2007) Strategies and New Developments in the Generation of Patient-
Specific Pluripotent Stem Cells.  Cell Stem Cell, 1: 39-49.  July 2007.  
http://download.cell.com/cell-stem-cell/pdf/PIIS1934590907000185.pdf 
 
 20 
Chapter-2:  Stem Cell Applications 
Jacob Aschettino 
 
 
 The ability of stem cells to grow and differentiate into other tissues provides the basis of the new 
field of regenerative medicine in which stem cells are used to replace aged or diseases tissues.  Some 
types of stem cells have been in use for treating diseases for over 50 years, while other types of stem cells 
have only recently been discovered.  Their use in tissue regeneration could provide important cures for 
untreatable diseases and provide a better understanding of human biology (Chapman, 1999).  
However, controversy often follows many of science's great innovations, and this holds true for 
stem cells, as their use will have a strong social impact.  For this reason, it is important for the 
public to have a well informed understanding of the applications for which stem cells can be 
used (Chapman, 1999), as their benefits to society will have to be understood prior to discussing 
their ethics in later chapters.  The purpose of this chapter is to describe how stem cells have been 
used to treat different categories of diseases, bringing the reader up to speed on the treatments for 
some specific disorders. 
 Stem cell research has already developed treatments for many diseases over the years, 
some large and some small. However, to focus the scope of this chapter, the treatment of five 
specific diseases with stem cells will be discussed:  leukemia, damaged heart muscle, diabetes, 
Parkinson's disease, and strokes.  Each subheading will begin with a discussion of what the 
disease is, summarize the contribution of animal models for the treatments, discuss any human 
clinical or pre-clinical data if it exists, and discuss possible future directions for the research. 
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Stem Cell Treatment of Leukemia 
 Cancer is one of the most widespread and rapidly progressing diseases in the world. 
Although cancer can affect almost any part of the body, cancers result from the cell's inability to 
control its own growth, division, or differentiation. In the case of leukemia, the cancer cells 
occur in the blood or the bone marrow, resulting in high levels of immature white blood cells that 
crowd the area surrounding the bone marrow (Thomas et al., 1977). As a result, the bone marrow 
is not able to produce enough healthy mature white blood cells for the immune system. 
Leukemia has many forms found in both children and adults, and can be acute or chronic. The 
type found in children tends to be more rapidly progressing and aggressive, due to the fact that in 
adolescence, a child's immune system is more active because they encounter more germs and are 
less aware of the health risk associated with their behaviors. This active immune system means 
that the bone marrow usually produces large quantities of white blood cells, which can be a 
problem if the cells become cancerous and their production becomes exponentially greater, and 
the produced cells are immature. Leukemia can also be classified by the type of cells (myeloid or 
lymphoid) that develop the cancer (Healthwise Inc., 2011). Myelogenous leukemia occurs when 
the cancer takes hold of the type of marrow that produces red blood cells, some white blood 
cells, and platelets. Lymphocytic leukemia occurs when the cancer affects the type of marrow 
that produces lymphocytes, the infection fighting cells in the body. 
 One of the most important types of stem cells that have been used for decades to treat  
leukemia is the hematopoietic stem cell (HSC).  HSCs are the stem cells in bone marrow that are 
responsible for producing all types of new blood cells. In the late 1950's, scientists began 
experimenting with animals for possible treatments for leukemia. The scientists would start by 
administering a lethal dose of radiation to a model animal such as a rat or a primate to destroy 
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their endogenous bone marrow, then would inject a suspension of healthy bone marrow taken 
from a compatible donor.  If the healthy marrow engrafted, it survived and replenished the 
destroyed hematopoietic cells allowing them to resume their normal function. These early animal 
trials are the precursor to the bone marrow transplants we now perform in hospitals worldwide. 
 Bone marrow transplants were first performed in human patients around 1957 (Thomas et 
al., 1957), and they are now used to treat a wide variety of blood disorders with success rates in 
excess of 98% for some types of cancer, but is not successful for all types (Gratwohl et al., 
2010).  The procedure has been modified over the years to improve success.  Initially, it was 
thought that total body irradiation (TBI) was required; some treatments now avoid this if the 
tumor is localized, while others require TBI supplemented by other antileukemic drugs. 
Scientists have also experimented throughout the 1970's with different methods of injecting the 
healthy bone marrow, altering the site of injection, the number of cells, and the purity of the 
injected cell sample.  Some recent techniques select for HSCs from the marrow cells using a 
selection marker.  Although this marker is not well defined, most scientists believe CD34+ cells 
represent HSCs, so they select for them prior to injection.  New drugs have also been developed 
that can help the patient’s immune system cope with the after effects of the procedure, lowering 
the risk of graft rejection, while producing relatively few side effects.   
In addition, scientists are developing ways to increase the number of compatible donors, 
always in short supply.  Autologous bone marrow transplants use a patient’s own bone marrow 
cells for perfusion, hoping the cancerous cells have been removed.  Allogenic bone marrow 
transplants use a histo-compatible donor to provide the bone marrow, usually a parent or sibling 
because of their genetic similarity (Lucile Packard, 2012). Umbilical cord blood transfers use 
HSCs taken from cord blood donated at hospitals following birth (Viacord, 2011).  In this 
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procedure, HSCs from cord blood are differentiated, typed, and then implanted into a patient 
with unhealthy marrow.  Cord blood HSCs hold a promising future for transplants, as their HSCs 
appear to be less differentiated than HSCs from bone marrow, so there is less chance of rejection 
by the patient (Viacord, 2011). 
 All of these advancements for treating leukemia have been made within the last fifty 
years or so, and have become a well-established use of stem cells in our society. New and more 
advanced technologies are being introduced every day and will rapidly increase the progression 
of this field of research.  With the right funding and encompassing understanding, we can limit 
our biological vulnerability to leukemia and other cancers.  
 
Stem Cell Treatment of Damaged Heart Muscle 
 The heart serves as one of the most important muscles in the human body, ensuring a 
healthy flow of oxygen and nutrient rich blood throughout the body. The heart, like any other 
muscle, can become damaged and lose function.  The damage can happen in a variety of ways, 
but by far the most common occurs with a heart attack, which occurs in over 1 million 
Americans annually (American Heart Association, 2012). The coronary arteries directly 
surrounding the heart provide the channels for blood to reach the heart and can sometimes 
become blocked by small deposits of fat or protein that form plaque. This plaque may buildup in 
a coronary artery, or buildup elsewhere then breakoff and travel to a coronary artery to block it.  
At the plaque site, an inflammatory response forms including platelets that block blood flow, so 
the heart will literally begin to suffocate from lack of oxygen (WebMD, 2012). This can cause 
part, or all, of the heart muscle to die if untreated.  Other ways in which the heart muscle cells 
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can become damaged include drug addiction, congenital heart defects (defects you are born 
with), hypertension, and other debilitating diseases that tax the heart (Healthwise Inc., 2011). 
 Scientists are attempting to use stem cells to regrow damaged heart muscle cells, and 
with the exception of hematopoietic stem cells, this area of stem cell applications is the furthest 
in human clinical trials.  Human heart attack patients are already being tested in cell therapy 
experiments by injecting skeletal myoblasts (Menasché et al., 2001; Siminiak et al., 2004), bone 
marrow stem cells (Britten et al., 2003; Lunde et al., 2006; Schächinger et al., 2006), 
mesenchymal stem cells (Chen et al., 2004), and adult cardiac stem cells (GEN, 2011). Each of 
these different kinds of stem cells attempts to replenish the population of healthy cardiac cells in 
an area of damaged heart muscle.  Of the 27 human clinical trials performed to date using adult 
stem cells to treat heart attack patients,  12 were performed with bone marrow cells, 5 with 
peripheral blood mobilized HSCs, 2 with mesenchymal stem cells, and 8 with skeletal myoblasts 
(Stem Cell Therapy…..2012).  The end point of all the clinical trials was to verify safety and 
feasibility, not efficacy, so future experiments will be required to determine whether any of these 
treatments actually improve cardiac function. 
Bone marrow-derived stem cells were among the first to be tested in humans for therapy, 
and have shown some success in repairing damaged heart (Britten et al., 2003).  In a clinical 
study, 28 heart attack patients of various severities were given a transplantation of circulating 
blood (CPC) or bone marrow derived (BMC) progenitor cells, or stem cells that already have 
disposition to differentiate into heart tissue. The experiment showed that, four months after 
transplantation, the patients showed significant improvement in the remodeling and revitalization 
of their hearts, and a decrease in infarct size. As a supplemental experiment, the researchers 
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showed that the CPC and BMC progenitor cells ex vivo could migrate towards a gradient of 
growth factors, showing their capacity for effective remodeling (Britten et al., 2003).  
Adult cardiac stem cells (CSCs) were first identified in mice in 2003 as c-Kit
+
 cells 
(Beltrami et al., 2003), and were also later identified as Isl1
+
 cells in mice, rats, and humans 
(Laugwitz et al., 2005).  In mice, the Isl1
+
 cardiac stem cells cells were shown to be capable of 
differentiating into more than just cardiac muscle, and also formed smooth muscle and 
endothelial cells for forming new arteries and veins (Moretti et al., 2006).  The experiments with 
Isl1
+
 cells were extended to humans in 2009, showing that human Isl1
+
 cells can differentiate 
into multiple cardiac lineages (Bu et al., 2009).  The fact that regenerative adult cardiac stem 
cells exist in heart tissue suggests that the heart is not a terminally differentiated organ incapable 
of tissue replacement; it contains stem cells that allow its depleted cell types to replenish 
themselves on a small scale as needed.  Scientists hope these cells can help repair hearts in 
human clinical trials (Baker, 2009). 
With respect to embryonic stem (ES) cells, in early work with animal ES cells, scientists 
have found that pluripotent mouse ES cells injected into mice can differentiate into all the major 
types of cells in the heart (Klug et al., 1996).  Later, human embryonic stem (ES) cells were 
shown to be capable of differentiating into various cardiac lineages in vitro (Kehat et al., 2001), 
but these human ES cells have not been approved for treating patients due to ethical issues, and 
due to technical issues of sometimes forming tumors at the injection site.  
With respect to human induced pluripotent stem (iPS) cells, human iPS cells have been 
shown to be capable of differentiating into cardiac lineages in vitro (Burridge et al., 2011), but 
have not yet been tested in patients.  This experiment was performed at the Johns Hopkins 
Institute for Cell Engineering, and tested over 45 different experimental variables to define a 
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universal in vitro cardiac differentiation process for either ES cells or iPS cells.  The final 
method used a staged exposure to physiological (5%) oxygen, and optimized concentrations of 
morphogens BMP4 and FGF2, polyvinyl alcohol, serum, and insulin.  By using a highly 
controlled environment and chemically-specific medium, the scientists were able create cells that 
were structurally the same as cardiomyocytes and were responsive to cardiac drugs (Burridge et 
al., 2011).  This procedure could lead to a safe and viable way to produce an unlimited number 
of cardiac stem cells for future therapies. Human clinical trials will lead to a deeper 
understanding of any complications that follow injection. 
 Further research into the use of embryonic and/or adult stem cells to treat 
cardiomyopathy will hopefully provide a fuller understanding of how the heart can be repaired 
and its health maintained.  Injecting patients with adult stem cells is already improving cardiac 
function.  Hopefully in the near future, cell therapy will provide doctors with a new arsenal of 
treatments for heart attack patients.  
 
Stem Cell Treatment of Diabetes 
 Diabetes is a metabolic disease that affects the ability of the body to use glucose.  Type-I 
diabetes, also called juvenile onset diabetes, is caused by the body’s attack on pancreatic beta 
cells that produce insulin.  The inability to make the hormone insulin results in less glucose 
uptake into tissues from the blood,  resulting in hyperglycemia.  Type-II diabetes, also called 
non-insulin dependent diabetes, is the most common type and is caused by the body developing a 
resistance to insulin, also resulting in hyperglycemia (American Diabetes Association, 2012). 
This type of diabetes correlates with obesity, and is becoming increasingly common in children 
A third type of diabetes is called gestational diabetes, and occurs in some women who are 
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pregnant and have higher levels of blood glucose than normal. This is thought to be caused by 
the many hormonal changes that occur in a pregnant woman's body trying to regulate the 
exchange of nutrients from mother to child; as a result the body becomes resistant to insulin. 
Gestational diabetes is not very common, only effecting approximately 4% of births.  If  left 
untreated, it can lead to birth defects and a higher rate of miscarriage (WebMD
2
, 2012). Diabetes 
symptoms include excessive thirst, urination, or eating, and death in some instances (WebMD
2
, 
2012).  The current treatment for type-I diabetes is insulin injections to replace the insulin not 
produced from the damaged beta-cells.  But even with insulin injections, it is difficult to 
precisely control serum glucose levels, so hyperglycemia and hypoglycemia often result.  And 
the use of adult pancreatic islet transplant tissue into humans is hindered by the lack of donated 
tissue.  So scientists are currently trying to use stem cells to re-grow damaged pancreatic tissue 
to treat type-I diabetes. 
With respect to treating diabetic animal models with stem cells, the mice have shown 
restored normal glycemia when treated with mouse embryonic stem (ES) cells (Soria et al., 
2000), with hematopoietic stem cells (to produce T-cells that do not attack the pancreas) 
(Beilhack et al., 2003), with induced pluripotent stem (iPS) cells derived from mouse skin cells 
(Alipio et al., 2010), or with human ES cells that differentiated in vivo into insulin-producing 
cells (Kroon et al., 2008).  The iPS cell approach is most exciting if it can be expanded to 
humans because it does not destroy any embryos. 
 With respect to human diabetic patients, patients have not yet been injected with stem 
cells; however, several studies have proven that human ES cells can differentiate into insulin-
producing cells in vitro (Assady et al., 2001; Lumelsky et al., 2001; Seguev et al., 2004; 
D’Amour, 2006).  
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 For the experiment in which mouse diabetic models were treated with adult 
hematopoietic stem cells (HSCs) (Beilhack et al., 2003), a group of researchers at Stanford 
university conducted an experiment with non-obese diabetic (NOD) mice, one of our best models 
for type-I diabetes.  In this model, the T-cells of the immune system attack the beta-cell tissue, as 
occurs in type-I patients.  If autoreactive T-cells (directed against the pancreas) are transferred 
from NOD mice into normal mice, the normal mice get diabetes, showing that the T-cells destroy 
the pancreatic tissue.  If the autoreactive T-cells in the NOD mice are destroyed by radiation or 
chemotherapy and replaced with normal T-cells derived from bone marrow HSCs, the mice do 
not develop diabetes, offering hope for diabetic patients (Beilhack et al., 2003). 
 Another experiment using diabetic mice showed that a mouse ES cell clone (IB/3x-99) 
was able to engraft into NOD mice and differentiate into insulin producing cells in vivo. A group 
of these cells (1*10
6
) were implanted into the spleen of diabetic animals.  After one week their 
hyperglycemia had ceased, and after 4 weeks their weight normalized (Soria et al., 2000) 
 With respect to human ES cells, in 2001, scientists in Israel performed an experiment to 
determine whether human pluripotent embryonic stem cells cultured in vitro would respond to 
signals and differentiate into insulin secreting cells (Assady et al., 2001). By seeding a gel 
medium with non-essential amino acids and other nutrients required for cell growth, the 
scientists followed the previously published methods for inducing differentiation in mouse ES 
cells, and were successful. The cells produced insulin in response to an increase in glucose 
(Assady et al., 2001). However, the percentage of insulin producing cells was not determined, 
and if found to be low, scientists must do more experiments to increase the efficiency.   
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 Advancements like these hopefully will allow doctors all over the world to provide viable 
and effective treatments to diabetes patients.  There is no doubt that further research will expand 
the horizon of available treatment options for these patients. 
 
Stem Cell Treatment of Parkinson's Disease 
 Parkinson's disease (PD) is neurodegenerative conditon that affects the part of the brain 
that controls movement and coordination.  PD is progressive, eventually causing rigid stiff joints, 
tremors in the extremities, and slow lathargic movements.  Approximately one million people 
currently live with PD in the United States, and over 10 million worldwide,  most of whom are 
over the age of fifty (Parkinson's Disease Foundation, 2012). Though there has been decades of 
research, the cause of PD is unknown, and there is no cure.  In PD, the dopamine producing 
neurons of the substantia nigra die.  Dopamine is a neurotransmitter that functions in movement; 
without it movement is hindered (National Center for Biotechnology Information, 2011).  
Current treatments for PD include the use of chemical precursors to dopamine, or drugs that 
increase neuromuscular transmission, but these drugs act transiently, and are not a cure. 
 Scientists are attempting to develop methods for treating PD with stem cells to regrow 
dopaminergic neurons.  The very first cell therapy treatments for PD involved injecting patients 
with fetal tissue transplants isolated from aborted fetuses (Madrazo et al., 1988; Lindvall et al., 
1989; Freed et al., 2001, Mendez et al., 2002), but this technique proved to be highly 
controversial, and the public worried about the inducement of abortions solely to support medical 
research, so this technique is no longer used.  With respect to stem cell treatments, PD patients 
have been treated with adult olfactory mucosal stem cells (Levesque, 2005), and with adult 
neuronal stem cells (Ertelt, 2009). 
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 In one interesting study with a rat PD model, scientists designed an experiment to 
determine whether human embryonic stem cells could serve as a replacement for the damaged 
dopamine-producing neurons in a rat PD model (Ben-Hur et al., 2004).  They were able to 
generate a large number of neuronal progenitors in vitro using a mytomycin-C-treated mouse 
fibroblast feeder layer in gelatin-coated tissue culture dishes. They then tranplanted these human 
neural progenitor cells into the striatum of the rats and observed differentiation of the cells into 
dopamine-producing neurons.  Although this led to significant behavioral recovery from PD 
symptoms, it also caused brain teratoma formation (large tissue-encapsulated tumors) in 20% of 
the treated rats (Ben-Hur et al., 2004), which appears to be a recurring problem with some ES 
cell treatments.  
 With respect to the fetal tissue transplant approach, in an experiment in the late 1980's 
conducted on two consenting adults with PD, doctors grafted cells from a fetal adrenal gland and 
fetal substantia nigra into the caudate nucleus of the brain (Madrazo et al., 1988).  Basal nuclei 
reside in an area of the brain responsible for body movement and coordination (MedicineNet Inc, 
2012).  Doctors chose the adrenal gland and the substantia nigra for tissue grafts because they 
are areas involved with dopamine production.  The procedure showed promise at first, with a 
reduction in tremors and behavioral improvements, but later the side effects of the procedure 
were significant and the grafted tissue did not integrate fully. This opened the door for other 
researchers to experiment instead with stem cells. 
 With regard to human embryonic stem cells, scientists have shown they can differentite 
into dopamine-producing cells in vitro (Perrier et al., 2004).  In 2004, Dr. Perrier and collegues 
tested several different species of ES cells (primates, mice, and humans) to try to determine a 
process of differention for dopamine-producing neuronal progenitors. In their experiment, 
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neuronal differentiation was induced using a modified stromal based-feeder system, where 
stromal cells are taken from bone marrow and used to prompt the differentiation of ES cells. The 
exact chemical nature of these stromal cells is unknown, however in this experiment MS5, 
FGF8, and SHH stromal growth factors were shown to induce the in vitro differentiation of ES 
cells into midbrain dopamine-producing cells (Perrier et al., 2004). The cells remained healthy in 
culture, but were never transplanted into any animal models or patients for testing. This 
experiment showed that it is possible to induce the differentiation of human ES cells into 
midbrain dopamine neuronal tissue.  
 PD is a debilitating disease for its victims and their loved ones, and future research can 
hopefully increase our understanding of its causes. Stem cells offer a potential treatment 
alternative that could become the capstone of a full recovery. 
 
Stem Cell Treatment of Strokes 
 A stroke occurs with a blockage in blood flow in the blood vessels leading to or inside 
the brain. This can cause cells upstream from the blockage to starve for oxygen and lose their 
function. This lack of oxygen can also occur when a blood vessel bursts open in the brain.  
Strokes are common among the elderly, and can be physically debilitating; in addition to a loss 
of speech, expression or or other mental capacities, patients can also experience paralysis of one 
side of the body or total loss of mobility (National Institute for Neurological Disorders and 
Stroke, 2012). 
 Scientists are researching the  possibility of using stem cells for regrowing damaged brain 
cells following a stroke.  Human stroke patients have already been treated with mesenchymal 
stem cells (MSCs) (Bang et al., 2005).  
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Scientists working with a rat stroke model used human ES cells to try to decrease the 
damaged area of the brain (Steinberg, 2008).  In this experiment at Stanford University’s School 
of Medicine, scientists spent months differentiating high numbers of neuronal precursors from 
human ES cells, which were then injected into the brains of host rats. They observed the 
neuronal precursors migrating to the lesion site, which began the repair of  damaged tissue 
(Steinburg, 2008).  A similar study done earlier by the same group showed that injection of 
undifferentiated ES cells into the brains of stroke induced rats also migrated to the lesion site and 
regenerated brain cells (Steinberg, 2004).  
 In a joint Korean-Canadian study, scientists working with animal models also found that 
the injection of mesenchymal stem cells and bone marrow stromal cells derived from humans 
can aid in the recovery of the animals from stroke.  Doctors injected both types of stem cells into 
rat stroke models, and in both cases observed cell migration to the infarct site and regeneration of 
damamged neuronal tissue (Stem Cells Useful….2008). 
 In a 2005 study done with human subjects, scientists selected 30 patients with lesions in 
their brains or deficits like those of a stroke patient (Bang et al., 2005). They then administeered 
an injection of mesenchymal stem cells (MSCs) which they observed migrate to the infarct area 
and facilitate regeneration of the dead tissue. This was a significant improvement when 
compared with the control group who received no MSC injection (Bang et al., 2005). 
 A recent and promising procedure took place in 2006 in Kiev, Ukraine when a 50 year-
old chiropractor from New York had a stroke and wanted to try stem cell therapy. Dr. Rich 
James had a stroke, and was left with a whole side of his body completely immobilized. Though 
it is not known what type of stem cells were used, or the method of injection, months after the 
procedure was performed Dr. James was able to walk unassissted (Vega, 2006).  It is also not 
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clear from this type of uncontrolled experiment whether the patient would have improved on his 
own without the stem cell treatment. 
 
Chapter-2 Conclusions 
 These experiments show examples of the potential that stem cells have in regenerative 
medicine. Although human clinical trials are somewhat limited (outside using hematopoietic 
stem cells), and the data is scarce, the promise that the future research hold is priceless, and 
should lead to much more comprehensive treatment approaches for patients with a variety of 
diseases.  The applications of stem cells are exponentially expanding as we learn more about 
their properties.  The five diseases discussed here are only the tip of the iceberg when it comes to 
the potential uses of stem cells.  But as with any other innovation, there comes the complications 
of ethics and the boundaries created by regulations, which will be discussed next. 
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Chapter-3:  Stem Cell Ethics 
Stephen Dalton-Petillo 
 
 Even with the great promises of regenerative medicine, and the real or potential use of 
various kinds of stem cells to treat human disorders, all of this science is affected by one of the 
most controversial bioethical debates of our time, the ethics of researching, using, and harvesting 
stem cells.  Ethics is defined as the moral correctness of a specified conduct, and it is the moral 
correctness of harvesting a particular type of stem cell, the embryonic stem (ES) cell, that is the 
center of the debate.  The purpose of this chapter is to investigate the ethics of stem cells, 
especially ES cells. 
 
Introduction to Stem Cell Ethics 
As discussed in previous chapters, ES cells are harvested from the inner cell mass of a 5-
day old blastocyst embryo prepared by in vitro fertilization (IVF).  Harvesting the ES cells 
destroys the embryo, so the debate focuses on the status of the 5-day old embryo.  The status of 
an embryo is affected by political, religious, and personal views, which factor together to provide 
a complex topic.  Although researching and using stem cells in medicine points to a “whole new 
era of medicine” (Derbyshire, 2001), the center of the debate is whether the benefits of these 
potential breakthroughs are worth the detriments to the embryo. 
The main focus of the debate is on when life begins as an embryo.  A person or group’s 
decision on when life begins in an embryo ultimately determines their beliefs and outlooks on 
stem cell research.  It may surprise some people to learn that the embryo debate is not new, and 
in fact began decades ago with the advent of IVF technology, and the birth of Louise Brown, the 
world’s first test tube baby (BBC News, 1978).  There are typically three major thoughts about 
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embryo use.  1) One group believes that personhood begins at conception, and that all human 
embryos regardless of their age are a person with rights and privileges, and any harvesting or 
destruction of it is viewed as equal to killing a living person.  2) Another group believes that an 
embryo is a potential person but cannot be considered a person by itself.  If the embryo is not 
implanted into a womb, it cannot develop into a full human.  3) The last view is that the embryo 
is literally and physically a group of cells “that are no more alive or human than a tumor, [or] a 
virus” (Derbyshire, 2001).   
Generally, individuals who agree with the first two groups are against stem cell use and 
research, and those who agree with the third group are in favor of stem cell use and research.  
However, some individuals in the second group allow embryo usage under specific 
circumstances, so long as the embryo is respected and human lives are saved.  It is the potential 
cure of diseases and the potential for improving the quality human life that some people consider 
more morally right than protecting a cluster of cells that have yet to become anything substantial 
in comparison to  
The stem cell debate is complicated by the topic of cloning.  Harvesting ES cells from an 
IVF embryo is not cloning.  Therapeutic cloning involves isolating a skin cell nucleus from a 
patient, and injecting it into an enucleated egg, which is then grown to the blastocyst stage and 
ES cells isolated.  The ES cells are genetically identical to the patient who donated the skin cell 
nucleus, so should not be rejected by the patient.  Reproductive cloning is the same process just 
described, except the blastocyst embryo is implanted into a uterus for the purpose of live birth.  
Neither therapeutic nor reproductive cloning has been achieved with humans, but both have been 
achieved with animals.  Others believe that reproductively cloning humans will be the next step 
in line after ES cell isolation, and therapeutic cloning, and fear that allowing unregulated or 
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unrestricted implementation of parental nuclei in stem cells will pave the way for these practices 
(Derbyshire, 2001).  And regardless of a person’s views on cloning, ultimately, one’s viewpoint 
on when life begins in an embryo decides their stance for or against ES stem cell use. 
 Although the ethics debate of ES cells is important in science and politics, religion plays 
a very important role in how most people view this topic.  The five major religions: Christianity 
(and Catholicism), Judaism, Islam, Hinduism, and Buddhism, all have different stances on 
embryo research.  Despite this generalization, large religions often have different levels of 
followers, and some can disagree with a religion’s main stance.  This chapter will examine each 
major religion and their stance on embryo research, indicating where they believe life begins, 
and if there are any major disagreements within the religion important or prevalent enough to 
mention. 
 
Catholicism and Stem Cells 
 The first religion we will discuss is Catholicism, a form of Christianity led by the Pope.   
In 2009, Pope Benedict was quoted saying that, “Research into somatic stem cells merits 
approval and encouragement when it brings together scientific knowledge… and the ethic that 
postulates respect for human beings at every stage of their existence…” (Catholic Online, 2008).  
So, it is not true that Catholics disapprove of all stem cells, just ES cells.  It is well documented 
that most Catholics believe life begins at conception, so a 5-day old embryo is a living person 
(American Catholic Organization, 2006).  “If there has been – and there still is – resistance, it 
was and is against those forms of research that involve the planned suppression of human beings 
who are already alive, though they may not yet have been born…” (Catholic Online, 2008) was a 
quote from Pope Benedict in the same interview, indicating that manipulating or altering any 
 41 
form of human life is “devoid of humanity.”  The embryo is viewed by the religion, even at its 
earliest stages as an example of “the weakest [of life] among us” (Nairn, 2005), and susceptible 
to destruction through ES cell research.   
Interestingly, as is typical for a very large religion, not all members hold the exact same 
view on life’s origins.  Although the Pope and the majority of Catholics believe human life 
begins at fertilization, others believe it begins at birth, or anywhere in between.  With this 
variation, the church’s reluctance to use embryos for research is formed under the theory that “it 
is objectively a grave sin to dare to risk murder” (Nairn, 2005).  It is also believed that the point 
in which the soul is acquired by the human can never be accurately determined as occurring 
before or after birth, so this uncertainty also affects the debate.  The church generally disagrees 
with deriving more ES cell lines as this would cause the “destruction of more blastocysts” and 
“there would be at least an indirect encouragement… diluting the condemnation of the original 
destruction of human blastocysts” (Nairn, 2005). 
In addition, ES cell research not only poses the ethical problems of killing an embryo, but 
also “increasingly poses the ethical problem of deceiving the public as well” (Benedict Endorses 
Adult Stem-Cell, 2008).  Richard Doerflinger, the interim executive director of U.S. bishops’ 
Secretariat for Pro-Life Activities strongly believes in this and boldly made a claim in the same 
article that embryonic stem cells research has promoted a “series of deceptions” and in fact will 
not cure Alzheimer’s disease.  He fears that no change in this “deception” will cause science to 
lose its credibility (Catholic Online, 2008). 
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Non-Catholic Christians and Stem Cells 
The rest of the non-Catholic Christian faith, Protestant, Methodist, and other 
denominations have similar opinions to that of the Catholic Church, but there are some 
differences.  For example, Methodists believe that it is “morally tolerable to use existing 
embryos for stem cell research purposes” (United Methodist, 2004).  They believe that the 
potential therapeutic benefits from this research with already existing excess IVF embryos 
outweigh the wrong.  The use of embryos not introduced into the womb in reproductive efforts is 
considered “morally tolerable” as long as an embryo is not created for the sole purpose of 
research (United Methodist, 2004).  However, the Christian faith in general rejects the use of 
human embryos for research. 
 
Judaism and Stem Cells 
Judaism, in comparison with Christianity and Catholicism, encourages the research of 
both adult stem cells and embryos, with some restrictions.  The Jewish tradition states that 
Pikuach nefesh, the Preservation of life, is the “most important obligation of all, overriding 
almost all other laws” (Yearwood, 2006).  If the ES cells derived from destroyed embryos 
possess the ability to benefit society by preserving existing life, then this is in line with Jewish 
tradition and accepted.  According to the Jewish faith and law, it is commonly accepted that “a 
fetus prior to forty days gestation is not considered to be an actual person” and “destruction of 
such a [young] fetus is not forbidden by Jewish law” (Eisenberg, 2006).  In addition, the faith 
also permits the abortion of a fetus prior to 40 days following the same guidelines.  Since they 
believe an embryo may be destroyed during the specific time period for abortion, it most 
certainly can be used to further research in the embryonic stem cell field to save existing lives.  
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However, embryos after the forty day gestational period are considered to have human qualities, 
and thus there is a prohibition of retzicha (murder) mandated by Jewish law (Eisenberg, 2006).  
There has always been a debate whether using embryos is similar to “playing God” which to 
some is considered extremely wrong.  But two Jewish legal mandates encourage this based on 
the “two professions” of God Himself: teaching and healing. Thus, researching stem cells to 
further future therapeutic medical practices is viewed as behaving similar to God, and is 
condoned when it comes to medical research (Jakobovits, 2006).  And as with Christianity where 
not all members think alike, while these are the opinions of most Jewish leaders, and are in 
accordance with general Jewish tradition, it was specifically pointed out that all of these 
conclusions are not unanimous (Jakobovits, 2006). 
 
Islam and Stem Cells 
The Islamic stance on stem cell research is very similar to that of Jewish beliefs. The 
Islamic religion is very proactive when it comes to the support of research that will yield future 
medical benefits to help maintain a good quality of life.  In vitro fertilization is widely supported 
by Islamic people, and logically argues that instead of wasting the thousands of excess IVF 
targeted for destruction after the couple has enough children, why not use them for research?  
Adult stem cell research is widely supported and is less controversial than ES cell use, and the 
Islamic faith encourages this form of an alternative research, although potentially it is less useful 
(Siddiqi, 2002).  The Islamic people similarly believe in the distinction between the point of 
potential life of an embryo and actual life; not only distinguishing actual from potential by 
embryo age in the womb, but also applying the distinction to an embryo in the womb versus a 
dish (IVF).  The potential of an IVF embryo to grow into a human being if implanted into the 
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uterus is acknowledged, but the fact that it is not yet a human being prior to the forty day mark 
affirms the difference.  So there is nothing wrong in doing this research, “especially if this 
research has a potential to cure diseases” (Siddiqi, 2002).  The Islamic people feel that if this is 
the case with stem cell research, then it is “not only allowed, but it is obligatory to pursue this 
research” (Siddiqi, 2002).  However, they do believe that lines should be drawn with regard to 
the reckless destruction of embryos solely for research purposes.  Basically, ES cell research 
should be limited to only spare embryos from IVF, rather than creating and destroying an 
embryo solely for the purpose of research.  Also the potential malpractice of doctors having their 
patients produce more embryos than needed for IVF is a common fear (Siddiqi, 2002), so this 
must be controlled.  Overall, stem cell research is encouraged within Islam using excess IVF 
embryos (near day 5), but using an embryo after day forty is murder. 
  
Hinduism and Stem Cells 
Hinduism, the most predominant religion of the subcontinent of India, has morals, ethics, 
and ideas slightly different than that of the aforementioned religions, yet it still poses an 
intriguing stance on stem cell ethics.  One of the core beliefs of the Hindu doctrine of non-
violence (ahimsa) is that all life is sacred, and that all of God’s creations (which are everything) 
must be respected (Bahnot, 2008).  With that said, another major belief is that the law of nature 
says that in order for one to survive, another life must be taken, such as humans eating plants or 
animals.  According to the ancient Rishis (divine sages), there are a variety of levels of 
consciousness in existence, with plants at the lowest level, then animals, then humans.  The 
highest level of consciousness beings, humans, must be protected which justifies the killing of 
lower levels of consciousness beings, plants and animals (Bahnot, 2008).  Many practices such 
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as Yoga were created to rid the body of illnesses and promote a healthy lifestyle with the idea of 
prolonging one’s life.  Comparing this “necessity to take lives” belief to the goals of science and 
stem cell research can justify using an embryo, with the promise that it will further benefit the 
quality of life of living people (Bahnot, 2008).    
Although this is just one opinion on the use of embryos through Hinduism teachings, 
other groups of Hindus believe that using embryos is unacceptable, as this would constitute 
harming another living thing due; conception is viewed as “a soul’s rebirth from a previous life” 
(Knowles, 2012).  Some believe that the soul’s rebirth occurs between three and five months, 
while others think it happens at the seven month point, resulting in varying beliefs within the 
religion.  Hinduism has no “official” leaders of the entire religion, causing slight confusion to 
general stances (Knowles, 2012).  Regardless, Hindu believers are supportive of using adult stem 
cells as they cause no harm, yet aim to help heal others. 
 
Buddhism and Stem Cells 
Buddhism is very similar to Hinduism in its teachings, thought, and morals.  With respect 
to embryos and ES cells, there is much variance.  Buddhism like Hinduism agrees that the 
therapeutic use of adult stem cells is acceptable because it doesn’t cause any harm to life.  Also 
similar to Hinduism is the fact that Buddhism has no official group that makes statements on 
behalf of the religion (Keown, 2004), which leads to confusion when trying to generalize the 
stance for stem cells for Buddhism as a whole.  There is no singular sacred text like in 
Christianity to define when life begins or what is right or wrong.  Mostly, there are teachings 
within Buddhism that pose morals and ideals for a particular lifestyle.  Buddhists have been said 
to adopt a similar belief to Hinduism that conception marks the birth of a person, but then again 
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only some of Buddhists believe this (Knowles, 2012).  There are two separate tenets in the 
Buddhist teachings that apply to embryos: one is against the act of harming others, and another is 
for the pursuit of knowledge.  The first tenet argues against harming embryos, while the second 
tenet would favor it based on the fact that it holds promise for improving human life in the future 
(Knowles, 2012).  On the other hand, the Buddhist belief in rebirth says that life starts at 
conception, which means that the newly fertilized embryo is considered a person and “entitled to 
the same moral respect as an adult human being” (Keown, 2004).  Yet going against the idea of 
rebirth, the use of an embryonic stem cell could be viewed as a donation to help benefit the lives 
of others, which would not be considered an act of evil in Buddhist doctrine (Promta, 2004).  It is 
interesting to note that Buddhists understand that there are two different views on this (and other 
subjects), an empirical and non-empirical view.  The empirical view is the opinions of those in 
the community, while the non-empirical view belongs to the authorities of the religion or its 
teachings (Promta, 2004).  This dual view confirms the vast differences of stances in Buddhism 
on the use of embryos and ES cells, based on different codes of conduct. 
 
Induced Pluripotent Stem Cell Ethics 
Induced pluripotent stem (iPS) cells, are adult skin fibroblast cells forced into a 
pluripotent state by introducing 2-4 transcription factors (or the genes encoding them) into the 
skin cells.  As discussed in Chapter-1, these iPS cells appear to be similar to ES cells in that they 
can be used to make a large variety of tissues.  The main difference is that the skin cell 
undergoing the treatment does not have to be harvested from a human embryo, thus eliminating 
the main reason for not using ES cells (Deem, 2009; Brind’Amour, 2009).  One of the most 
overlooked concerns of using IVF embryos is the effect of harvesting the eggs on women.  This 
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procedure is a relatively complex medical procedure, and can have complications such as 
infections that can be life threatening to the donor.  In addition, if money is paid to egg donors, it 
might induce poor women into undergoing an egg donation procedure they otherwise would 
never undergo (Baylis, 2008).  The act of iPS cell induction has been revised from the original 
method of using viruses encoding 4 transcription factors, to using the proteins themselves, which 
erased many health issues potentially induced by the viral vectors.  In addition, the original 4 
transcription factors included c-Myc oncogene which induced tumor formation in some cases, 
and this has now been replaced by a protocol using only 2 factors that does not cause cancer 
(Kim et al., 2008).   
Although there are many advantages to this new iPS cell research, there is still some 
ethical apprehension.  Even though iPS cells do not require human embryos, through the process 
of being induced to a pluripotent like state some ethicists fear that the iPS cells could eventually 
become totipotent, and be capable of making a living being if implanted.  In this case their ethics 
would be similar to an IVF embryo (Brind’Amour, 2009), although this has never been shown to 
be the case.  So some ethicists argue destroying iPS cells is equivalent to destroying potential life 
(Cohen and Brandhorst, 2008). 
 
Chapter-3 Conclusions 
The final part of this chapter is an assessment of my opinions with regards to the ethical 
issues described in this chapter.  I am not against the use of embryos for research, as long as the 
woman donating the eggs for IVF fertilization is willing to undertake a procedure with potential 
side effects.  Although the IVF embryo has potential life, it also has the potential to save existing 
lives, so prior to the forty day mark I believe it is just a collection of cells.  If a man and woman 
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who donated the egg and sperm for IVF are willing to donate their excess fertilized embryos for 
research purposes, let it be their decision and no one else’s.  I am in favor of using excess IVF 
embryos originally created for reproductive purposes, as this is a great way to use these embryos 
instead of wasting them from being discarded.  It is similar to recycling.  If the “product” is 
being used for one purpose and either fails or was not needed, then its reuse for something else 
makes sense.  Having said that, I am also in favor of using embryos created solely for research 
purposes using paid donors.  If somebody is willing to donate egg and sperm and also receive a 
compensation for it, then it is entirely up to them, so long as they are aware of the potential 
health risks of egg donation and understand what the ES cells will be used for.  There are much 
more dangerous things that people in this world agree to do or take part in that yield almost no 
benefit to mankind (smoking, base jumping, etc.). 
I think that to calm the majority of people who think using ES cells is murder, using adult 
stem cells whenever possible should be encouraged.  I also do not think it is right to limit the 
amount of federal dollars for ES cell research due to political and religious opinions, based on 
the fact that the cells have so much potential for therapeutic breakthroughs.  So ultimately, using 
adult stem cells whenever possible is a good compromise.  I am also in favor of using iPS cells if 
possible.  I think that iPS cells are a clever and crafty discovery to avoid the main issue of using 
IVF embryos.  It is a little ridiculous for those who think that iPS cells are exactly like embryos 
and have the potential to make a living being, because this has never been shown.  iPS cells lack 
the ability to grow into a form of life even if implanted into a uterus.  I think people should be 
more opposed to the idea of reproductive cloning, than worrying about iPS cells. 
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Chapter-4: Stem Cell Legalities 
Joseph Szerszunowicz 
 
As is typical for all controversial technologies, laws have been enacted to control the funding for 
stem cell research.  The benefit to society of regenerative medicine through stem cells is 
unparalleled, but as was discussed in Chapter-3 some types of stem cells are ethically 
controversial.  This is especially true for embryonic stem (ES) cells that destroy an embryo when 
isolating them. The legalities of stem cells is a fascinating blend of science and politics; 
whichever administration is in office dictates they types of laws enacted, and the policies vary 
from state to state.  For the past three presidents (Clinton, Bush, Obama), the United States has 
held widely varying stem cell policies, and the next administration in January may have an 
entirely different policy.  Pro stem cell bills under one president’s administration are sometimes 
completely nullified by the next administration. In some cases, individual states such as 
California, New Jersey, and Massachusetts have approved their own bonds to fund ES cell 
research during times lacking federal funding.  In addition, the laws on stem cells vary from 
country to country.  The purpose of this chapter is to discuss federal and state laws regulating 
embryo and ES cell research in the U.S and abroad.  The last three U.S. presidential 
administrations have been the most involved with embryo and stem cell legislation mainly due to 
the timing of the stem cell technologic boom. 
 
The Clinton Administration and Stem Cells 
 President Clinton tried to set the stage for a golden age of stem cell research with the 
National Institutes of Health Revitalization Act of 1993 (NIH Revitalization Act…1993). ‘Under 
this act the NIH was given direct authority by President Clinton and Congress to fund human 
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embryo research for the first time’ (Dunn, 2005). This was a monumental step for researchers 
who believed that stem cells could lead to the eradication of most of mankind’s incurable 
diseases. With this new direct authority over human embryonic stem cell research, the NIH had 
to form a panel to oversee this research and to be held accountable to the public and congress. 
The NIH formed a group of experts called the NIH Human Embryo Research Panel (Robinson, 
2005). This panel included scientists, ethicists, and public policy experts whose role was to 
consider the morals and ethics of embryo experiments and determine what should be federally 
funded. The panel came to the conclusion that experiments that used excess embryos prepared 
for in vitro fertilization (IVF) to derive new ES cell lines should be federally funded.  The NIH 
Human Embryo Research Panel attempted to kick start a boom in stem cell research by allowing 
stem cell farming from embryos to be financially backed by the government. Armed with large 
federal funding, the possibility of new advancements in medicine and rehabilitation looked 
promising. 
However, this “golden age” of embryo research was short lived. In 1996, the Dickey-Wicker 
Amendment was enacted by congress. The Dickey-Wicker Amendment states that: 
SEC. 509. (a) None of the funds made available in this Act may be used for-- 
(1) the creation of a human embryo or embryos for research purposes; or  
(2) research in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk 
of injury or death greater than that allowed for research on fetuses in utero under 45 CFR 46.204(b) and 
section 498(b) of the Public Health Service Act (42 U.S.C. 289g(b)).  
(b) For purposes of this section, the term `human embryo or embryos' includes any organism, not protected 
as a human subject under 45 CFR 46 as of the date of the enactment of this Act, that is derived by 
fertilization, parthenogenesis, cloning, or any other means from one or more human gametes or human 
diploid cells. (Kearl, 2010) 
 
 
With this 1996 amendment in effect, the earlier recommendation made by the NIH to federally 
fund embryo research was nullified. The Dickey-Wicker Amendment was written by Republican 
Representatives Jay Dickey and Roger Wicker. With this ban on federal funding, the only way to 
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continue to explore ES cell research was with private funding.  The Dickey-Wicker Amendment 
seemed to make Clinton’s NIH stop dead in its tracks towards making any further 
recommendations on how to fund stem cell research. 
 In 1999, there was a breakthrough for ES cell research. Harriet Rabb, the top lawyer for 
the Department of Health and Human Services, made a brilliant legal decision observation 
involving the privately funded lab of James Thompson. In 1998, Thompson was the first person 
to isolate human embryonic stem cells (Thomson et al., 1998).  The NIH under Clinton knew this 
discovery was an immense finding, so Rabb pointed out an obvious loophole in the Dickey-
Wicker Amendment, concluding that:  although ‘federal funds could not be used to make stem 
cells because this would involve creating or destroying a human embryo, which directly violates 
the Dickey-Wicker Amendment, on the other hand the stem cells themselves are not under the 
definition of “human embryo”, thus the Dickey-Wicker Amendment does not apply to stem cells. 
These soon became the standard guidelines under the Clinton Administration in August of 2000’ 
(Dunn, 2005). The federal government was now allowed to fund experiments involving ES cells, 
but it was up to the privately owned research labs to derive the stem cells in the first place. 
President Clinton heavily endorsed these guidelines, knowing that research from human embryo 
experiments could solve many problems with currently incurable diseases. This Rabb legal 
decision solidified the Clinton Administration as the first stepping stone on the road to federal 
funding for stem cell research.    
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The Bush Administration and Stem Cells 
President Bush had very opposing views than President Clinton on embryo research. As soon as 
Bush assumed office in 2001, ES cell research in the U.S. began to suffer.  President Bush’s 
Secretary of Health and Human Services Tommy Thompson, 
“ordered a review of Rabb's legal decision. Then, the Bush Administration told the NIH to cancel its plans 
to review grant applications—pending completion of the HHS review. If the Bush Administration had done 
nothing, the NIH would have proceeded to review the applications and to finance those that were 
successful. Instead, that process was halted, a decision that saddened, angered, and frustrated supporters of 
human embryonic stem cell research.” (Dunn, 2005) 
 
The Bush administration was seeking to immediately stop any progress the Clinton 
administration previously made towards federally funded ES cell research. Within the same year, 
on August 9
th
 , 2001 President Bush would fully undo any strides President Clinton made in ES 
cell research funding: 
“On August 9th, 2001, Former President George W. Bush announced that federal funds may be awarded 
for research using human embryonic stem cells if the following criteria are met: 1) The derivation process 
(which begins with the destruction of the embryo) was initiated prior to 9:00 P.M. EDT on August 9, 2001.  
2) The stem cells must have been derived from an embryo that was created for reproductive purposes and 
was no longer needed.  3) Informed consent must have been obtained for the donation of the embryo and 
that donation must not have involved financial inducements.” (NIH.gov, 2001) 
 
Days later on August 11, 2001, President Bush made a radio address to the people of the United 
States about the nation’s next step in stem cell research. He was recorded stating the following:  
“Embryonic stem cell research offers both great promise and great peril.  So I have decided we must 
proceed with great care.  As a result of private research, more than 60 genetically diverse stem cell lines 
already exist.  They were created from embryos that have already been destroyed, and they have the ability 
to regenerate themselves indefinitely, creating ongoing opportunities for research.  I have concluded that 
we should allow federal funds to be used for research on these existing stem cell lines where the life and 
death decision has already been made.  
     Leading scientists tell me research on these 60 lines has great promise that could lead to breakthrough 
therapies and cures.  This allows us to explore the promise and potential of stem cell research without 
crossing a fundamental moral line, by providing taxpayer funding that would sanction or encourage further 
destruction of human embryos that have at least the potential for life.” (Bush, 2001). 
 
Thus, President Bush within 8 months of attaining office halted federal funding for ES cell 
research, and also reduced the number of qualified ES cell lines available for testing. The only 
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saving grace for ES cell research was that federal funding would still be allowed for the pre-
existing sixty stem cell lines that President Bush agreed on. Unfortunately, the so-called 60 ES 
cell lines proved to be far less, as further experiments indicated many of the cell lines were 
genetically identical to each other, were genetically damaged, or were aged, so scientists feared 
that had far fewer cell lines for work with than originally promised (Holden and Vogel, 2002).  
 Stem cell issues did not come up again for President Bush until July 19, 2006, when he 
used his power to veto a bill for the first time to deny the passing of the Stem Cell Research 
Enhancement Act of 2005 (Stem Cell….2005). This bill would help alleviate the harsh 
restriction on ES cell lines that President Bush first enacted when he first took office. The bill 
passed through both the House of Representatives and the U.S. Senate by majority votes, but the 
final vote in the house was not sufficient to override the president’s veto:  “the House voted 235 
to 193 yesterday to override Bush, falling short of the threshold and negating the need for a 
Senate override attempt” (Babington, 2006).  Even though the bill failed to override Bush’s veto, 
the votes showed that the government outside of President Bush, was trying to take a step in 
funding ES cell research.  
 In 2007, Bush would again veto a bill of the same nature on June 20, 2007. The bill was a 
rehash of the previous research enhancement act, and Congress hoped for a better chance of 
overriding any veto (Stem Cell….2007).  But again President Bush vetoed the bill, stating: 
“scientific advances now allow researchers to pursue the potentially lifesaving work without 
destroying human embryos” (Fletcher, 2007). The president put more emphasis on the use of 
stem cells collected from umbilical cords and amniotic fluid rather than destroying human 
embryos. This veto put President Bush on the wrong side of Congress, and made sure that any 
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further stem cell related bills or legislations would be placed on the shoulders of the next 
administration.  
 
The Obama Administration and Stem Cells 
 Like President Bush, President Obama made it abundantly clear that stem cells were a hot 
issue, but this president took a different approach. Instead of following his own feelings on the 
matter, President Obama said that “his administration would make scientific decisions based on 
facts not ideology” (Childs and Stark, 2009).  So on March 9, 2009 President Obama signed an 
executive order to end Bush’s 2001 ban of federally funding ES cell research. However, 
President Obama’s lift of the ban meant he had to determine new guidelines for allowing the 
funding, so he turned to the NIH and gave them 120 days after the signing of his executive order 
to create new guidelines (Childs and Stark, 2009). The 2009 NIH revised guidelines involving 
stem cell research opened the door for the use of ES cells that were originally deemed 
untouchable by the Bush Administration. The guidelines allowed for research on ES cells: 
I. that were created using in vitro fertilization for reproductive purposes and were no longer needed for this 
purpose;  
II. that were donated by individuals who sought reproductive treatment (hereafter referred to as "donor(s)") 
and who gave voluntary written consent for the human embryos to be used for research purposes; and  
III. for which all of the following can be assured and documentation provided, such as consent forms, written 
policies, or other documentation, provided:  
IV. All options available in the health care facility where treatment was sought pertaining to the embryos no 
longer needed for reproductive purposes were explained to the individual(s) who sought reproductive 
treatment.  
V. No payments, cash or in kind, were offered for the donated embryos.  
VI. Policies and/or procedures were in place at the health care facility where the embryos were donated that 
neither consenting nor refusing to donate embryos for research would affect the quality of care provided to 
potential donor(s).  
VII. There was a clear separation between the prospective donor(s)’s decision to create human embryos for 
reproductive purposes and the prospective donor(s)'s decision to donate human embryos for research 
purposes. Specifically:  
VIII. Decisions related to the creation of human embryos for reproductive purposes should have been made free 
from the influence of researchers proposing to derive or utilize hESCs in research. The attending physician 
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responsible for reproductive clinical care and the researcher deriving and/or proposing to utilize hESCs 
should not have been the same person unless separation was not practicable.  
IX. At the time of donation, consent for that donation should have been obtained from the individual(s) who 
had sought reproductive treatment. That is, even if potential donor(s) had given prior indication of their 
intent to donate to research any embryos that remained after reproductive treatment, consent for the 
donation for research purposes should have been given at the time of the donation.  
X. Donor(s) should have been informed that they retained the right to withdraw consent for the donation of the 
embryo until the embryos were actually used to derive embryonic stem cells or until information which 
could link the identity of the donor(s) with the embryo was no longer retained, if applicable.  
XI. During the consent process, the donor(s) were informed of the following:  
XII. that the embryos would be used to derive hESCs for research;  
XIII. what would happen to the embryos in the derivation of hESCs for research;  
XIV. that hESCs derived from the embryos might be kept for many years;  
XV. that the donation was made without any restriction or direction regarding the individual(s) who may receive 
medical benefit from the use of the hESCs, such as who may be the recipients of cell transplants.;  
XVI. that the research was not intended to provide direct medical benefit to the donor(s);  
XVII. that the results of research using the hESCs may have commercial potential, and that the donor(s) would 
not receive financial or any other benefits from any such commercial development;  
XVIII. whether information that could identify the donor(s) would be available to researchers.  
(Holden, 2009; Childs and Stark, 2009)  
 
The 2009 NIH guidelines loosely followed the same procedures originally made for the Clinton 
Administration a decade before, but allowed for donated ES cell lines derived from discarded 
IVF embryos to receive federal funding, however federal funding could not be used to derive the 
lines in the first place. The same general rules applied as earlier for how the ES cells would be 
donated; no money could be paid to the donors, and the donor must have written consent to 
donate the ES cell lines. 
Obama’s lift of the 2001 ban now allowed fully equipped government-funded labs to be used for 
research on ES cells, increasing the available lines to 400 to 1,000 (Hayden, 2009). This is a 
huge improvement from the original 21 lines that could receive funding under President Bush, 
hopefully allowing new discoveries to be made to save lives.  Many embryos that were 
scheduled for termination can be recycled and put to good use.  Because the law prohibits federal 
funding to derive the ES cells, that portion of the research must be funded by private funds  
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(Holden, 2009). The author of this chapter believes that the ban lift by President Obama was 
indeed a choice made using common sense based on science, instead of the ideology of one man. 
 
State Governments’ on Stem Cells  
 During the constant fight over whether federal funding could be allowed to fund ES cell 
research over three administrations (Clinton, Bush, Obama), various state governments stepped 
into the debate and created their own laws and regulations to support the research to make crucial 
breakthroughs in medical technology with ES cells. 
Massachusetts and Stem Cells 
 Massachusetts took a very active role in making ES cell research possible in the United 
States during the strict policies established in the Bush era. In May 2005, at the 187
th
 Meeting of 
the General Court of Massachusetts, state legislators declared in section one of the Act 
Enhancing Regenerative Medicine in the Commonwealth: 
(a) human embryonic stem cell research and other research in the life sciences and regenerative medicine present a 
significant chance of yielding fundamental biological knowledge from which may emanate therapies to relieve, on a 
large scale, human suffering from disease and injury;  
(b) the extraordinary biomedical scientists working within institutions of higher education, research institutes, 
hospitals, biotechnology companies and pharmaceutical companies can contribute significantly to the welfare of 
mankind by performing outstanding research in these fields; and 
(c) it shall be the policy of the commonwealth to actively foster research and therapies in the life sciences and 
regenerative medicine by permitting research and clinical applications involving the derivation and use of human 
embryonic stem cells, including research and clinical applications involving somatic cell nuclear transfer, placental 
and umbilical cord cells and human adult stem cells and other mechanisms to create embryonic stem cells which are 
consistent with this chapter.? It shall further be the policy of the commonwealth to prohibit human reproductive 
cloning. (An Act Enhancing Regenerative…2005) 
This 2005 Act, approved by a wide margin that overturned Governor Mitt Romney’s veto, states 
that the medical potential of stem cells is too great to keep from being hindered because of 
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ethical or moral arguments. People can be helped by stem cells now, and the state of 
Massachusetts saw it as unfair to the people who needed that help.  Great strides could be made 
in the field, and it did not seem logical to hinder the progress. In 2007, to aid in the progression 
of research, Governor Deval Patrick announced a 1.25 billion dollar funding initiative for stem 
cell research (Marks, 2007). Much of the funding went to the founding of the Massachusetts 
Human Embryonic Stem Cell Bank, located in Worcester, MA (Marks, 2007).  The bank is 
located in The University of Massachusetts Medical School (UMMS) and provides an excellent 
research atmosphere free of most restrictions for both local and international scientists (Shelton, 
2007).  
California and Stem Cells 
California is another state that took a very pro stem cell research stand during the strict Bush 
administration. On November 2, 2004, California voters approved Proposition 71, also known as 
the ‘California Stem Cell Research and Cures Act’ (LAO, 2004). This act allowed for $3 billion 
dollars in obligated bonds to be dispersed as loans and grants for stem cell research and research 
facilities. The act also established the California Institute of Regenerative Medicine (CIRM) that 
would control how the research money would be dispersed throughout the state, much like the 
NIH does on the national level. The money would be borrowed from California’s General Fund, 
and would begin to be paid off after ten years (LAO, 2004).  This was a clever way to work 
around the federal stem cell funding issue during the Bush era. 
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Various Other States on Stem Cells     
 Other states also followed suit and approved their own ES cell initiatives, while states 
voted to prohibit embryo research.  Table-I shows a list of various US states and their stance on 
embryo and ES cell research. 
 
State/Jurisdiction 
Statute Section 
 
Specifically 
permits research 
on fetus/embryo 
 
Restricts research 
on aborted fetus/ 
embryo 
 
Consent 
provisions to 
conduct research 
on fetus/embryo3 
Restricts research 
on fetus or 
embryo resulting 
from sources 
other than 
abortion 
 
Restrictions of 
purchase/sale 
human tissue 
for research 
Arizona 
§§36-2302, 2303 
No Yes, prohibits 
research on aborted 
living/non-living 
embryo or fetus 
No Yes, prohibits the 
use of public monies 
for cloning for 
research 
No 
Arkansas 
§§20-17-802, 20-16-
1001 to 1004 
No Yes, prohibits 
research on aborted 
live fetus 
Yes, consent to 
conduct research on 
aborted fetus born 
dead 
Yes, prohibits 
research on cloned 
embryos 
Yes, prohibits 
sale of fetus/fetal 
tissue 
California Health & 
Safety 2004 
Proposition 71 §§ 
123440, 24185, 
12115-7, 125300-320 
Yes, permits 
research on adult 
and embryonic stem 
cells from any 
source 
Yes, prohibits 
research on aborted 
live fetus 
Yes, consent to 
donate IVF embryo 
to research 
Prohibits sale of 
embryos and 
oocytes; prohibits 
payment in excess 
of the amount of 
reimbursement of 
expenses to be 
made to any 
research subject to 
encourage her to 
produce human 
oocytes for the 
purposes of medical 
research 
Yes, prohibits 
sale for the 
purpose of 
reproductive 
cloning or for 
stem cell 
research 
Connecticut §§4-
28e; 19a-32d et seq. 
Yes, on embryos 
before gastrulation 
(a process during 
embryonic 
development) 
No Yes, consent to 
donate IVF embryo 
to research 
No Yes, prohibits 
payment for 
embryos, 
embryonic stem 
cells unfertilized 
eggs or sperm 
donated following 
IVF treatment  
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Florida 
§390.0111 
No Yes, prohibits on 
aborted live fetus 
No No No 
Illinois 
720 ILCS 510/6, 
510/12.1 
Executive Order 6 
(2005);410 ILCS 110/1 
et seq. 
Yes, permits 
research on 
embryonic stem 
cells, embryonic 
germ cells and adult 
stem cells from any 
source 
Yes, prohibits on 
aborted living/ 
nonliving fetus 
Yes, written consent 
to perform research 
on cells or tissues 
from a dead fetus 
other than from an 
abortion 
Yes, prohibits 
research on 
fetus/fertilized 
embryo; prohibits 
funding under E.O. 
6 (2005) of research 
on fetuses from 
induced abortions 
and the creation of 
embryos through 
the combination of 
gametes solely for 
the purpose of 
research 
Yes, prohibits 
sale of fetus/fetal 
tissue; prohibits 
purchase or sale 
of embryonic or 
fetal cadaveric 
tissue for 
research but 
permits 
reimbursement 
for removal, 
storage and 
transportation for 
research 
Indiana 
§35-46-5-1, 16-18-2-
5.5 
Yes, permits fetal 
stem cell research 
on placenta, cord 
blood, amniotic fluid 
or fetal tissue 
Yes, prohibits 
research on aborted 
living/non-living 
embryo or fetus 
Yes, consent 
required for fetal 
stem cell research 
Yes, prohibits 
research on cloned 
embryos 
Yes, prohibits 
sale of human 
ovum, zygote, 
embryo or fetus 
Iowa 
§§707C.4 
Yes, ensures that 
Iowa patients have 
access to stem cell 
therapies and cures 
and Iowa 
researchers may 
conduct stem cell 
research 
No No No Yes, prohibits 
transfer or 
receipt of the 
product of human 
reproductive 
cloning 
Kentucky 
§436.026 
No No No No Yes, prohibits 
sale of fetus/fetal 
tissue 
Louisiana 
§14: 87.2 
No No No Yes, prohibits 
research on 
fetus/embryo in 
utero, in vitro 
fertilized embryo 
No 
Maine 
22§1593 
No No No Yes, prohibits 
research on 
fetus/embryo born 
or extracted alive, 
only applies to in 
vitro fertilized 
embryos post-
Yes, prohibits 
sale of fetus/fetal 
tissue 
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implantation 
Maryland 
83A§5-2B-01 et seq. 
Yes, permits 
research on adult 
and embryonic stem 
cells 
No Yes, written consent 
to donate unused 
IVF material to 
research 
Yes, prohibits 
donation of unused 
oocytes for state 
funded stem cell 
research; cloning of 
an organism beyond 
the embryonic stage 
is prohibited 
Yes, prohibits 
valuable 
consideration for 
the donation or 
production of IVF 
material 
Massachusetts 
112§12J, 2005 SB 
2039 
Yes, on embryos 
that have not 
experienced more 
than 14 days of 
development (not 
including days 
frozen) 
Yes, prohibits 
research on 
embryo/live fetus 
Yes, written consent 
to perform research 
on a dead fetus and 
informed consent to 
donate egg, sperm, 
or unused 
preimplantation 
embryos created for 
IVF 
Yes, prohibits 
research on live 
embryo or fetus; 
also prohibits 
creation of fertilized 
embryo solely for 
research 
Yes, prohibits 
sale of neonate, 
embryo or fetus 
for illegal 
purposes; 
prohibits sale of 
embryos, 
gametes or 
cadaveric tissue 
for research 
Michigan 
§§333.2687-2688, 
§§333.16274-16275, 
333.20197, 
333.26401-26403, 
750.430a 
No Yes, live embryo/ 
fetus 
Yes, written consent 
of mother to donate 
dead embryo, fetus 
or neonate to 
research 
Yes, prohibits 
research on a live 
embryo or fetus, 
cloned embryo 
No 
Minnesota 
§§145.421, 422 
No No No Yes, prohibits 
research on a live 
embryo or fetus up 
to 265 days post 
fertilization 
Yes, permits the 
sale/purchase of 
cell culture lines 
from nonliving 
human conceptus 
Missouri 
§§188.036, 037 
No Yes, prohibits 
research on a fetus 
alive pre-abortion 
No No Yes, prohibits 
receipt of 
valuable 
consideration for 
aborted fetal 
organs or tissue 
Montana 
§50-20-108(3) 
No Yes, prohibits 
research on a live 
fetus 
No No No 
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Nebraska 
§§28-342, 346, 71-
7606 
No Yes, prohibits 
research on aborted 
live fetus or the use 
of state funds for 
research on fetal 
tissue obtained from 
an abortion 
No Yes, limits the use 
of state funds for 
embryonic stem cell 
research; 
restrictions only 
apply to state 
healthcare cash 
funds provided by 
tobacco settlement 
dollars 
Yes, prohibits 
sale, distribution 
or donation of 
viable aborted 
child 
New Hampshire 
§§168-B:1, 15  
No No No Yes, prohibits the 
maintenance of a 
unfrozen fertilized 
pre-embryo past 14 
days 
Yes 
New Jersey 
C.26:2Z-1 et seq.; 
C.2C:11A-1 
Yes No Yes No No 
New Mexico 
§24-9A-1, 3, 5 
No No No Yes, prohibits 
research on a 
fetus/embryo born 
or extracted alive, 
only applies to in 
vitro fertilized 
embryos post-
implantation 
Yes, prohibits 
abortion for the 
purpose of selling 
the fetus to 
researchers 
New York  
Public Health Law 
Article 2, Title 5A 
Yes, permits 
research on adult 
and embryonic stem 
cells from any 
source 
No No   
North Dakota 
§14-02.2-01, 2; 2003 
HB 1424 
No Yes, prohibits 
research on a 
living/non-living 
embryo or fetus 
Yes, requires 
consent to conduct 
research on a 
nonliving fetus or 
embryo other than 
from an abortion 
Yes, prohibits 
research on a fetus 
born or extracted 
alive; cloned 
embryos 
Yes, prohibits the 
sale of a fetus to 
be used for illegal 
purposes 
Ohio 
§2919.14 
No Yes, prohibits 
research on a 
living/non-living 
embryo or fetus 
No No Yes, prohibits 
sale of fetus or 
fetal remains 
from an abortion 
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Oklahoma 
63 §1-735 
No Yes, prohibits 
research on a 
fetus/embryo 
No No Yes, prohibits 
sale of fetus or 
fetal remains 
Pennsylvania 
18 §§3203, 3216 
No Yes, prohibits 
research on a live 
embryo or fetus 
Consideration may 
not be given to 
mothers consenting 
to research; in 
cases involving 
abortion, consent 
must be provided 
after decision to 
abort 
No Yes, 
consideration 
may not be given 
to mothers 
consenting to 
research or other 
transferring 
tissue except for 
expenses 
involved in actual 
retrieval, storage, 
etc. 
Rhode Island 
§11-54-1 
No No Yes Yes, prohibits 
research on a 
fetus/embryo born 
or extracted alive, 
only applies to in 
vitro fertilized 
embryos post-
implantation 
Yes, prohibits 
sale of neonate, 
embryo or fetus 
for illegal 
purposes 
South Dakota 
§§34-14-16, 17, 20; 
34-23A-17 
No Yes, prohibits 
research on a 
living/non-living 
embryo or fetus 
No Yes, prohibits 
research on embryo 
outside of a 
woman's body; 
research on cells or 
tissues derived from 
an embryo outside a 
woman's body 
Yes, prohibits 
sale of embryo 
Tennessee 
§39-15-208 
No No Yes, consent 
required to conduct 
research on aborted 
fetus 
No Yes, prohibits 
sale of aborted 
fetus 
Texas Penal 
Code §48.02 
No No No No Prohibits sale of 
fetus/fetal tissue 
Utah 
§§76-7-301, 310 
No No No Yes, prohibits 
research on a live 
fetus, fertilized 
embryo post-
implantation1 
Yes, prohibits 
sale of fetus/fetal 
tissue; also 
prohibits sale of 
live unborn 
children, which is 
not defined, but 
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are referred to in 
abortion statute1 
Virginia 
§32.1-162.32-2 
No No No May prohibit 
research on a 
cloned embryo or 
fetus2 
Yes, prohibits 
shipping or 
receiving of the 
product of human 
cloning for 
commerce2 
Wyoming 
§35-6-115 
No No No No Yes, prohibits 
sale, distribution 
or donation of 
live or viable 
aborted child, 
defined to include 
embryos, for 
experimentation 
(Source: National Conference of State Legislatures, 2008) 
 
International Views on Stem Cell Research 
 The US is not the only country enacting policies to control stem cell research.  Many 
countries such as England, Sweden, and China have led the way to supporting embryo research. 
 
China and Stem Cells 
 China has long approved the use of embryos in research (discussed in Chapter-3), but 
their poor oversights of researcher qualifications, and loose laws for protecting intellectual 
property rights has come under some scrutiny. As a result, on May 1
st, 2009 China’s Stem Cell 
Transplantation Department enacted new laws regulating new biotechnologies, including stem 
cell treatments (Stem Cell Transplantation Dept.…2011).  The 2009 law called for more 
qualified directors running stem cell research facilities; any director must have 3 years of 
experience as a senior or technical position in a previous health institute. The clinic in question 
must also have had a technical audit, and pass standards established by a board of appropriate 
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authorities (Stem Cell Transplantation Dept.…2011).  To work on stem cells, any institution 
must meet the following criterion: 
In order to apply for approval, medical institutions should submit a feasibility study report, including: 
 The basic profiles of medical technology, including domestic and international applications, indications, 
contradictions, side effects, technical line, quality control measures, efficacy of standards, assessment, 
treatment and other medical technology with the risks , efficacy, cost and treatment comparison. 
 Main technical personnel’s qualification, relevant curriculum vitae, medical equipment, facilities and other 
auxiliary conditions, risk assessment and contingency plans. 
 Clearance from the medical ethics review body. 
The approval may not be granted under the following conditions: 
 The clinical application of medical technology in the technical review process is deemed to be ineffective. 
 Does not comply with the regulations of the appropriate administrative department of health. 
 The clinical application of medical technology did not pass the technical audit. 
 Beyond the scope of the registered medical subjects. 
The license to practice stem cell treatment will be revoked effective immediately in the following conditions 
 The respective medical technology has been abolished or prohibited by the Ministry of Health.  
 Should there be any variation in the equipment, facilities, key professionals from what is specified in the 
clinical application.  
 Should there be any adverse effects arising from the medical technology employed. 
 Medical quality and medical safety hazard. 
 Ethical shortcomings of medical technology. 
 Inaccurate clinical application of medical technology.  (Stem Cell transplantation Dept.….2011) 
 
Thus, in China, although their ethics does not generally prevent working with embryos and ES 
cells, their government needed to provide stronger oversight of scientist qualifications. 
 
Iran and Stem Cells 
There are also countries where religion does not appear to inhibit stem cell research whatsoever.  
Iran is an example of a balance between religious morals and science. Iran is a constitutional 
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Islamic republic, yet stem cell research flourishes (Erik, 2011). There are no laws that prohibit or 
regulate stem cell research, but instead their research is guided by Islamic ideals and their laws 
(Fatwa) are interpreted from these ideals by an Islamic scholar (Erik, 2011). “Ayatollah 
Khamenei, Iran’s religious leader issued a stem cell fatwa in 2002, stating that experimentation 
with human embryonic stem cells is consistent with Shiite Islam, thus making stem cell research 
possible in Iran” (Erik, 2011).  Thus, Iran is an interesting case of a nation that has no conflict 
morally about using ES cells because the Islamic religion dictates that life does not begin until 
the soul enters the body, which is well after the blastocyst stage when ES cells are derived.  
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PROJECT CONCLUSIONS 
 
 
 Based on the research performed for this project, the authors believe that the use of stem 
cells in medicine is practical and has the potential to treat many diseases, both chronic and 
terminal. Although the source and use of ES cells is controversial, these authors do not believe 
that embryo destruction is murder for a 5-day old surplus IVF embryo.  The authors agree that 
iPS cells and adult stem cells should be used whenever possible in place of ES cells, if they have 
been shown to be as efficient at treating that specific disease.  The type of stem cell used for 
treatments or research should be case specific, and based on the needs and demands of the case. 
Excess IVF embryos originally created for reproductive purposes slated for discard provide the 
best sourcing of ES cells, and unlike the current Obama administration we believe in allowing 
federal funding to help support this endeavor. The Obama administration currently allows 
private funding to derive new ES cell lines from IVF embryos, and federal funding to support 
research on the ES cells themselves.  In lieu of using surplus IVF embryos, paid egg donors 
should be an auxiliary source of ES cells, a practice not currently allowed in the U.S. under the 
Obama administration.  Iran’s policies for stem cell sourcing and research best reflect our 
personal views and beliefs, as their loose restrictions on ES research helps to further promote 
developments in the field.     
 
